Drug Profile
Research programme: cancer therapeutics - Debiopharm/EPFL
Alternative Names: Debio 0826Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Debiopharm
- Developer Debiopharm; Swiss Federal Institute of Technology - Lausanne
- Class Peptides; Small molecules; Venoms
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Switzerland
- 15 Apr 2011 Debio 0826 is still in early research for Cancer in Switzerland
- 02 Sep 2008 Early research in Cancer in Switzerland (unspecified route)